Drug intelligence / Profile preview

PRO CAR-301

Development stage: Preclinical
Lead developer: PromiCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

PRO CAR-301 is an autologous, CD33-directed chimeric antigen receptor (CAR) T-cell therapy being developed by PromiCell Therapeutics for the treatment of acute myeloid leukemia (AML). Exclusively licensed from Memorial Sloan Kettering Cancer Center (MSK), the therapy utilizes the next-generation "SAVVY/IL-18" armoring platform. This platform is engineered to express the potent immunological cytokine interleukin-18 (IL-18) to enhance anti-tumor immune responses and modulate the tumor microenvironment, enabling the targeting of both antigen-positive and antigen-negative tumor cells. Preclinical studies have demonstrated superior potency compared to standard CD33-specific CAR T therapies. PromiCell anticipates submitting an Investigational New Drug (IND) application to the FDA by the end of 2025, with Phase 1 clinical trials planned to commence in 2026.

Other names: CD33-directed SAVVY/IL-18 armored CAR T cell therapy

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on PRO CAR-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO CAR-301.

Explore the full profile